Metastatic or locally recurrent breast cancer
Item
1. metastatic or locally recurrent breast cancer,
boolean
C0278488 (UMLS CUI [1])
C2986682 (UMLS CUI [2,1])
C0678222 (UMLS CUI [2,2])
Age
Item
2. 18 years of age or older,
boolean
C0001779 (UMLS CUI [1])
her-2/neu status
Item
3. her-2/neu positive (3+ by immunohistochemistry or fish +),
boolean
C1512413 (UMLS CUI [1])
Inclusion Criteria
Item
4. one of the following
boolean
C1512693 (UMLS CUI [1])
Hormone therapy
Item
1. currently receiving hormonal therapy or are candidates for such or,
boolean
C0279025 (UMLS CUI [1])
Trastuzumab
Item
2. being considered for trastuzumab or,
boolean
C0338204 (UMLS CUI [1])
Cancer progression on trastuzumab
Item
3. their cancer has progressed on trastuzumab
boolean
C1947901 (UMLS CUI [1,1])
C0338204 (UMLS CUI [1,2])
Gynaecological status
Item
1. pregnant or lactating women.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Prior malignancy
Item
2. prior or concurrent malignancies except treated basal cell or squamous carcinoma of the skin or in situ cancer of the cervix or any other cancer treated and presumed cured more than five years prior to study entry.
boolean
C2735088 (UMLS CUI [1])
Currently receiving chemotherapy, immunotherapy, adenoviral gene therapy or biological cancer therapy
Item
3. currently receiving chemotherapy, immunotherapy, adenoviral gene therapy or biological cancer therapy. [note: concurrent hormonal therapy (tamoxifen,aromatase inhibitors, or megace) is permitted.].
boolean
C0521116 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C0521116 (UMLS CUI [2,1])
C0021083 (UMLS CUI [2,2])
C0521116 (UMLS CUI [3,1])
C0860404 (UMLS CUI [3,2])
C0521116 (UMLS CUI [4,1])
C1531518 (UMLS CUI [4,2])
Date of trastuzumab treatment
Item
4. treatment with trastuzumab within 4 weeks prior to first dose of vaccine therapy.
boolean
C0011008 (UMLS CUI [1,1])
C0338204 (UMLS CUI [1,2])
Hemoglobin measurement, granulocyte count, lymphocyte count, platelets
Item
5. hemoglobin < 80 g/l or granulocytes < 1.5 x 109 /l or lymphocytes < 1.0 x 109 /l or platelets < 100 x 109 /l.
boolean
C0518015 (UMLS CUI [1])
C0857490 (UMLS CUI [2])
C0200635 (UMLS CUI [3])
C0005821 (UMLS CUI [4])
Liver enzymes, liver metastases
Item
6. baseline liver enzymes (ast or alt) greater than 3 times upper limit of normal or greater than 5 times upper limit of normal if liver metastases present and/or bilirubin greater than 50 mmol.
boolean
C1287351 (UMLS CUI [1])
C0494165 (UMLS CUI [2])
C1278039 (UMLS CUI [3])
CD4 cell count
Item
7. cd4 cells < 0.5 x 109 /l
boolean
C0519835 (UMLS CUI [1])
Brain metastases
Item
8. patients with documented brain metastases.
boolean
C0220650 (UMLS CUI [1])
Acute Illness affecting vaccination
Item
9. patients with any acute illness that would interfere with vaccination
boolean
C4061114 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0042196 (UMLS CUI [1,3])
Immunosuppression
Item
10. any patients requiring concurrent immunosuppressive therapy (e.g. corticosteroids).
boolean
C0021079 (UMLS CUI [1])
ECOG performance status
Item
11. eastern cooperative oncology group (ecog) performance status of > 2.
boolean
C1520224 (UMLS CUI [1])
Life expectancy
Item
12. patients with a life expectancy of less than 6 months.
boolean
C0023671 (UMLS CUI [1])
Residency
Item
13. geographic inaccessibility which would preclude follow-up. patients registered on the trial must be treated and followed at the jewish general hospital.
boolean
C0035182 (UMLS CUI [1])
Informed consent
Item
14. failure to give written informed consent.
boolean
C0021430 (UMLS CUI [1])
Left ventricular ejection fraction
Item
15. baseline left ventricular ejection fraction (lvef) < 55% by echocardiography or muga scan.
boolean
C0428772 (UMLS CUI [1])